UCM Technologies Inc. Presented a Revolutionary Three-Biomarker Signature Test for Early Stage Detection of Non-Small Cell Lung Cancer at the American Society of Clinical Oncology 2023 Meeting in Chicago IL
CHICAGO, IL / ACCESSWIRE / June 4, 2023 / UCM Technologies has utilized a breakthrough combination of biomarkers (CA-62, CEA and CYFRA 21-1) to detect lung cancer at its earliest stages (stages I-II) with
United States British Columbia Joel Goodman Dynacare Labcorp Technologies Inc Personalized Treatment
Source: finanznachrichten.de